Crossmark

Multiple first-line therapeutic strategies to mitigate artemisinin resistance: cost analysis of a pilot study from a health system perspective in Kaya health district, Burkina Faso

Crossref DOI link: https://doi.org/10.1186/s12936-025-05493-5

Published Online: 2025-08-07

Update policy: https://doi.org/10.1007/springer_crossmark_policy

Authors

Guissou, Rosemonde M.

Kaboré, Jean Moïse T.

Soulama, Issiaka

Hien, Denise

Nombré, Yacouba

Tiono, Alfred B.

Burri, Christian

Sirima, Sodiomon B.
Funding

Funding for this research was provided by:

Medicines for Malaria Venture (PO18/00879, PO18/00879, PO18/00879, PO18/00879, PO18/00879, PO18/00879, PO18/00879, PO18/00879)
License Information

Text and Data Mining valid from 2025-08-07

Version of Record valid from 2025-08-07
More Information

Article History

Received: 3 April 2025

Accepted: 23 July 2025

First Online: 7 August 2025

Declarations

:

: The study received approval from the Burkina Faso Health Research Ethics Committee (clearance no. 2018–8-113) []. Informed consent was obtained from all respondents before the interviews.

: The authors declare no competing interests.

Document is current

Any future updates will be listed below